Calton & Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Calton & Associates’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,826	Closed	-$208K	–	305
2022 Q4	$208K	Buy	+1,826	New	+$152K	0.08%	255
2022 Q2	–	Sell	-2,243	Closed	-$236K	–	369
2022 Q1	$236K	Sell	2,243 -1,329	-37%	-$130K	0.07%	299
2021 Q4	$384K	Sell	3,572 -72	-2%	-$7.85K	0.1%	216
2021 Q3	$399K	Sell	3,644 -30	-0.8%	-$3.11K	0.09%	232
2021 Q2	$344K	Sell	3,674 -120	-3%	-$11K	0.07%	268
2021 Q1	$349K	Buy	+3,794	New	+$320K	0.07%	246
2020 Q4	–	Sell	-2,912	Closed	-$226K	–	403
2020 Q3	$226K	Sell	2,912 -2,217	-43%	-$153K	0.05%	293
2020 Q2	$285K	Buy	+5,129	New	+$219K	0.06%	234
2020 Q1	–	Sell	-8,711	Closed	-$315K	–	394
2019 Q4	$315K	Buy	8,711 +177	+2%	+$5.43K	0.06%	248
2019 Q3	$232K	Buy	+8,534	New	+$221K	0.05%	287

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Calton & Associates's HZNP Position: Q1 2023 in Review

Calton & Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 1,826 shares — an estimated $208K sold.

Calton & Associates first reported a position in HZNP in Q3 2019 and held it in 10 quarters. The position peaked at $399K in Q3 2021. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Calton & Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Calton & Associates sold 1,826 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $208K.
Calton & Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2019 and held it in 10 quarters.
Calton & Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $399K in Q3 2021.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Calton & Associates's 13F filing for Q1 2023, filed 19 Apr 2023.